Breathing New Life into Diagnostics: Plasmion’s SICRIT® Technology

FHS
June 11, 2024
12:47 pm

Revolutionizing Non-Invasive Diagnostics with Plasmion’s SICRIT Breath Analysis.

MASH revival with over $2.5bn for innovator drug partnership deals in 2024 – Pharmaceutical Technology

Share this article Source: GlobalData, Pharma Intelligence Center, Deals Database* (Accessed 20 March 2024) ©GlobalData. Metabolic dysfunction-associated steatohepatitis (MASH) innovator drugs witnessed an over $2.5bn

April 2, 2024

MASCT by Hengrui Yuanzheng Biotechnology for Solid Tumor: Likelihood of Approval

MASCT is under clinical development by Hengrui Yuanzheng Biotechnology and currently in Phase I for Solid Tumor.

January 9, 2024

Tiny imaging device could advance gastrointestinal cancer detection

Gastrointestinal cancers (GCs) are among the most common forms of cancer and account for as much as one-third of all cancer deaths worldwide.

February 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.